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MicroRNAs (miRNAs) are small non-coding RNAs that can negatively regulate gene expression at the 
post-transcriptional level through the RNA-induced silencing complex (RISC)-mediated inhibition. Because of 
the imperfect and short seed-binding region of the target sequences, miRNAs hold capacity for multi-targeting 
and are able to regulate a wide range of cellular functions and signaling. Numerous researches have revealed 
that dysregulated miRNAs are closely associated with cancer progression. Moreover, genome-wide screening 
shows that the expression profile of miRNAs can serve as biomarkers for early diagnosis, stratifying patient 
outcome, and predicting treatment efficiency for cancer patients. Hence, seeking and dissecting the detailed 
mechanisms of cancer-associated miRNA may provide a new avenue for cancer targeting therapy. This review 
discussed the current proposed mechanisms of miR-135b involvement in cancer progression and tissue 
differentiation, both of which are considered as functional equivalents. The regulatory network of miR-135b are 
also addressed to further clarify the potential oncogenic role of miR-135b. 
To cite this article: Ching-Wen Lin, et al. MicroRNA-135b as therapeutic target in cancers. RNA Dis 2014; 1: e410. doi: 
10.14800/rd.410. 
The role of miR-135b in lung cancer progression 
Several lung cancer-associated miRNAs have recently 
been identified. Among them, miR-135b antisense stands out 
for its therapeutic potential or its oncogenic role 
[1-3]
. An
up-regulated miR-135b is highly associated with poor overall 
survival in non-small cell lung cancer (NSCLC). Conversely, 
LZTS1 and LATS2, the downstream targets of miR-135b, 
are associated with better overall survival of patients with 
NSLCL when their proteins show stronger expression 
[1]
. The
ectopic expression of miR-135b has also been shown to 
promote cancer cell invasion, migration, and 
anchorage-independent growth in vitro and in vivo. The 
oncogenic mechanism is via the suppression of LZTS1 and 
multiple components of the Hippo pathway. Moreover, 
miR-135b antagonists not only efficiently lessens tumor 
burden but also reduces lung metastatic capability in a 
xenograft model (Fig. 1). 
The various oncogenic functions of miR-135b may be 
attributed to its multi-targeting ability, which involves 
different mechanisms during tumor progression. However, 
the oncogenic roles of miR-135b on cancer stemness and 
drug-resistance are yet to be clarified.  
The role of miR-135b in mesenchymal stem cell 
development  
During neuro-ectodermal (NE) development, TGF- 
β/BMP signaling is important in maintaining the 
pluripotency and self-renewal ability in human embryonic 
stem cells. The TGF-β/ BMP signaling can be suppressed by 
miR-135b 
[4]
. In addition, PAX6 is a critical protein for
human NE cell fate determinant that can up-regulate 
miR-135b during NE development. The miR-135b 
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subsequently suppresses the mRNAs of BMPR2, TGF-R1, 
SMAD5, and ACVR1b, by restricting the differentiating 
direction of human embryonic stem cells (hESC)
 [4]
.  
The miR-135b is also engaged in the fate-determination of 
mesenchymal cells by involving the differentiation lineages 
of muscles and bones 
[5, 6]
. The osteoblastogenesis of 
pre-myoblast mesenchymal cells is controlled by the potent 
osteogenic morphogene, bone morphogenetic protein-2 
(BMP2) 
[6]
. At the same time, BMP-2 can downregulate 
miR-135b during the BMP2-mediated C2C12 osteogenic 
differentiation, while miR-133, a myogenesis-promoting 
miRNA, is reduced, thereby restricting C2Cl2 to 
osteogenesis 
[7]
. Evidence suggests that in the presence of 
miR-135 and miR-133, mesenchymal stem cells undergo 
myogenesis instead of osteogenesis. 
Similarly, miR-135b expressions is the most severely 
downregulated one among the investigated 157 miRNAs 
during the osteogenesis of unrestricted somatic stem cells 
(USSCs) 
[8]
. These results depict the fact that the timing and 
place of miR-135b are properly controlled by tissue- or 
organ-specific factors, which in turn may adjust and 
coordinate the downsteam network and regulate 
mesenchymal stem cell differentiation.   
For the same reason, the inappropriate expression of 
miR-135b may obstruct cell lineage commitment. For 
example, multiple myeloma (MM) is composed of 
uncontrolled and proliferative plasma cells in bone marrow, 
with a hallmark of osteoblast inhibition and osteoclast 
activation within its micro-environment niche. Bone 
marrow-derived mesenchymal stem cells (BM-MSCs) 
isolated from patients with MM have significantly higher 
miR-135b expression as compared to those from normal 
donors 
[9, 10]
. In addition, miR-135b inhibitors can restore the 
impaired osteogenic phenomenon by relieving the 
miR-135b/smad5 pathway. Thus, miR-135b may be an 




The expression level of miR-135b is tightly regulated by 
tissue- specific micro-environment niches during the MSC 
fate-determination (Fig. 1). The MSCs are capable of 
differentiating into osteoblasts, adipocytes, chondrocytes, 
myoblasts, and non-mesenchymal tissues like 
neuro-ectodermal cells and hepatocytes 
[11-14]
. The 
miR-135b-mediated circuitry networks are distinct and 
fluctuated during diverse tissue-differentiation lineages, 
especially on neuro-ectodermal cells and osteoblasts. The 
up-regulation of miR-135b by PAX6 in hESC or MSCs helps 
neural cell fate determination by suppressing several 
components of the BMP and TGF- pathways.  
On the other hand, miR-135b is suppressed by BMP2 
during osteogenic cell commitment. Thus, a reciprocal 
negative feedback loop is formed between miR-135b and the 
BMP signaling pathway. This may restrict the divergent gene 
Figure 1. The molecular network miR-135b regulated in tissue development and the 
progression of cancer. 
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expression profile within distinct stem cell lineages (Fig. 1).  
Aberrant expression of miR-135b in cancers  
Aside from controlling the development of normal 
embryonic stem cells, aberrant miR-135b expression has 
been observed in various types of cancers, including colon 
cancer, prostate cancer, pancreatic ductal adenocarcinoma, 
anaplastic large-cell lymphomas (ALCLs), mammary 
carcinomas, and lung cancer 
[15-20]
. A vast number of 
researches also reveal that miR-135b is up-regulated not only 
in the tumor part of colorectal cancer but also in fecal 
samples 
[21-24]
. Furthermore, the expression of stool or 
tumoral miR-135b is positively correlated with stages of 
colorectal cancer lesions 
[15, 21, 22]
. These observations support 
the oncogenic role of miR-135b on cancer progression such 
that it may serve as a biomarker for cancer.  
Role of miR-135b in lung cancer and 
tumor-microenvironment  
The pulmonary epithelial surface is the first line of 
defense against environmental pollutants and antigens, and 
contains numerous defensive receptors and secretory 
cytokines. This immune-pulmonary cell microenvironment is 
the foundation of the pulmonary innate and/or adaptive 
immune systems
 [25]
. Recently, a research group has reported 
a series of results showing the dominant up-regulation of 
miR-135b in lung tissues upon exposure to cigarette smoke 
and nano-particles in mice models 
[26-28]
. The activated 
miR-135b is mediated through the IL-1a/IL-1R pathway, 
which consequently triggers either the acute or chronic 
pulmonary inflammation signaling cascade 
[26-28]
.  
The IL-1/IL-1R super family can recruit several cellular 
effectors via MyD88, which is connect to the central 
immuno-hub, the NF-B signaling
 [29]
. The promoter region 
of miR-135b as well as its host gene, LEMD1, have been 
identified as putative NF-B binding sites. In addition, 
non-small cell lung cancer (NSCLC) cells treated with 
TNF, a progenitor for provoking NF-B signaling, reveal 
signs of NF-B/ p65 binding on the miR-135b promoter. 
Moreover, the enhanced NF-B binding induces miR-135b 
expression, suggesting an extracellular inflammatory signal 
trigger for cellular miR-135b via NF-B cue, leading to the 




Although the role of inflammation in cancer progression is 
now well accepted, the detailed mechanisms involved remain 
unclear. NF-B is the most well-studied pro-inflammatory 
transcription factor in the recent decade, famous with being a 
central bridge between inflammation and cancers 
[30]
. 
Likewise, Matsuyama et al. have demonstrated the activation 
of a proto-oncogene, named Signal Transducer and Activator 
of Transcription 3 (STAT3), which intrinsically coalesce 
with NF-B to form an activating positive feed-forward loop. 
This signal goes together with IL-6, maintaining the 
inflammatory-tumor microenvironment in cancers 
[31, 32]
. 
Together with the aforementioned observations, both of 
NF-B and STAT3 transcriptionally promote the miR-135b 
expression 
[1, 31, 32]
. The expression of miR-135b may 
functionally provide a clue that may help uncover how 
inflammatory factors such as NK-B and STAT3 play 
decisive roles in multiple aspects of tumor progression. Thus, 
targeting miR-135b within the dysplastic tissues may be 
helpful in disrupting the cancer-inflammatory 
micro-environment.  
The miR-135b regulates Hippo pathway and downstream 
effector TAZ/YAP and promotes cancer stemness 
MiR-135b targets multiple Hippo components by directly 
down-regulating the proteins levels of LATS2, NDR2, 
MOB1b, and β-TrCP, and subsequently activating nuclear 
TAZ in NSCLC. Increased nuclear TAZ is associated with 
poor survival 
[1]
. In some cases, TAZ and YAP are not 
controlled by the core-Hippo axis, especially after the 
successive discovery of the novel components of Hippo 
branches 
[33, 34]
. However, the TAZ proteins eventually go 
through β-TrCP-mediated degradation 
[35]
, suggesting that 
miR-135b can promote TAZ activity not only through 
suppressing the Hippo-pathway but also prevent degradation 
by β-TrCP. Thus, miR-135b potentially leads the limitless 
growth of tumors by stabilizing the TAZ/YAP protein via 
regulation of a variety of different targets.  
Emerging studies reveal that activated TAZ endow breast 
cancer stem cells (CSCs) with a self-renewal capacity, which 
provides metastatic and chemo-resistant activities 
[36, 37]
. 
Furthermore, the loss of Hippo-related proteins, which 
belong to YAZ/YAP upstream negative regulators, results in 
uncontrolled tissue growth and increased population of 
cancer stem-like cells 
[38, 39]
. These findings suggest that the 
uncontrolled activation of TAZ and YAP is involved in 
regulating the population of cancer progenitor cells.   
The miR-135b as a therapeutic target for cancer and 
future prospectives  
Gene-based targeting approaches that specifically 
modulate disease-related gene expression for 
disease-treatment has robustly been investigated worldwide
 
[40]
. Since one miRNA in charge for a specific function or 
mechanism targets several downstream genes, it will be a 
remarkable smart way for disease-targeting therapy. For 
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instance, miR-135b inhibits tumor growth and metastasis by 
suppressing multiple tumor suppressors and pathways, 
including the Hippo pathway, LZTS1, APC, FOXO1, DAPK, 
as well as MTSS-1 (metastasis suppressor-1) 
[18, 22, 24, 31]
. In 
addition, using miR-135b inhibitors, several researchers have 
shown that silencing of miR-135b mitigates tumor burden, 
relieves lung metastatic nodules, and even rescues 
APC-knockout caused phenotypes 
[18, 22]
.  
Furthermore, miR-135b displays immuno-modulatory 
ability by cross-talking with pro-inflammatory cytokines and 
T cells in anaplastic large-cell lymphoma (ALCL) and in 
lung cancers 
[26, 31]
. Thus, miR-135 inhibition may further 
block the communication between tumor cells and its 
surrounding cancer niche.  
The generation of cancer is a complex, multi-step process 
that includes numerous aberrant gene expressions and 
dysregulation. Hence, the malformed gene networks are 
generated. These, in turn, allow cancer cells to gain 
properties like proliferation, motility, stemness, and drug 
resistance. The heterogeneity of tumor microenvironment 
governs an auto-feedback signal that nourishes the 
malignancy of dysplastic cells. These dysplastic cells further 
cross-talk with tumor-associated lymphoid cells by 
reciprocally secreting numerous growth factors and cytokines 
[41]
. Whether the elevated miR-135b serves as a hub in cancer 
cells and the surroundings, which reconstructs the 
microenvironment of the neoplastic area by fine-tuning the 
regulatory network in oncogenic process, warrants further 
investigation.  
Likewise, whether the expression of miR-135b enriches 
cancer-initiating properties and enhances drug-resistance in 
cells are important. Thus, targeting miR-135b may be a 
promising approach for disrupting the communication 
between tumor cells and its surroundings but also for 
impairing the oncogenic abilities of cancer cells. For these 
reasons, dissecting the detailed mechanism of miR-135b 
involvement in oncogenesis is necessary and targeting 
miR-135b using antagonists or antisense oligomer may have 
great potential for lung cancer therapy. 
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